Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma

per Maes, Ken, Breckpot, Karine
Publicat a Front Cell Dev Biol (2019)

Metabolic Features of Multiple Myeloma

per El Arfani, Chaima, De Veirman, Kim, Maes, Ken, De Bruyne, Elke, Menu, Eline
Publicat a Int J Mol Sci (2018)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

per Lub, Susanne, Maes, Ken, Menu, Eline, De Bruyne, Elke, Vanderkerken, Karin, Van Valckenborgh, Els
Publicat a Oncotarget (2015)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

per Maes, Ken, Menu, Eline, Van Valckenborgh, Els, Van Riet, Ivan, Vanderkerken, Karin, De Bruyne, Elke
Publicat 2013

The therapeutic potential of cell cycle targeting in multiple myeloma

per Maes, Anke, Menu, Eline, Veirman, Kim De, Maes, Ken, Vand erkerken, Karin, De Bruyne, Elke
Publicat a Oncotarget (2017)

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

per Maes, Ken, Mondino, Anna, Lasarte, Juan José, Agirre, Xabier, Vanderkerken, Karin, Prosper, Felipe, Breckpot, Karine
Publicat a Front Immunol (2021)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

per Vlummens, Philip, De Veirman, Kim, Menu, Eline, De Bruyne, Elke, Offner, Fritz, Vanderkerken, Karin, Maes, Ken
Publicat a Front Genet (2019)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response

per De Smedt, Eva, Lui, Hui, Maes, Ken, De Veirman, Kim, Menu, Eline, Vanderkerken, Karin, De Bruyne, Elke
Publicat a Front Oncol (2018)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma

per Wang, Jinheng, Faict, Sylvia, Maes, Ken, De Bruyne, Elke, Van Valckenborgh, Els, Schots, Rik, Vanderkerken, Karin, Menu, Eline
Publicat a Oncotarget (2016)

The genetic landscape of 5T models for multiple myeloma

per Maes, Ken, Boeckx, Bram, Vlummens, Philip, De Veirman, Kim, Menu, Eline, Vanderkerken, Karin, Lambrechts, Diether, De Bruyne, Elke
Publicat a Sci Rep (2018)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects

per De Beck, Lien, Melhaoui, Sarah, De Veirman, Kim, Menu, Eline, De Bruyne, Elke, Vanderkerken, Karin, Breckpot, Karine, Maes, Ken
Publicat a Oncoimmunology (2018)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells

per Wang, Jinheng, De Veirman, Kim, De Beule, Nathan, Maes, Ken, De Bruyne, Elke, Van Valckenborgh, Els, Vanderkerken, Karin, Menu, Eline
Publicat a Oncotarget (2015)

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

per Duvefelt, Charlotte Fristedt, Lub, Susanne, Agarwal, Prasoon, Arngården, Linda, Hammarberg, Anna, Maes, Ken, Van Valckenborgh, Els, Vanderkerken, Karin, Wiklund, Helena Jernberg
Publicat a Oncotarget (2015)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

per Yan, Siyang, Vandewalle, Niels, De Beule, Nathan, Faict, Sylvia, Maes, Ken, De Bruyne, Elke, Menu, Eline, Vanderkerken, Karin, De Veirman, Kim
Publicat a Cancers (Basel) (2019)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma

per Maes, Ken, Smedt, Eva De, Lemaire, Miguel, Raeve, Hendrik De, Menu, Eline, Van Valckenborgh, Els, McClue, Steve, Vanderkerken, Karin, De Bruyne, Elke
Publicat 2014

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential

per Bieghs, Liesbeth, Johnsen, Hans E., Maes, Ken, Menu, Eline, Van Valckenborgh, Els, Overgaard, Michael T., Nyegaard, Mette, Conover, Cheryl A., Vanderkerken, Karin, De Bruyne, Elke
Publicat a Oncotarget (2016)

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

per Favreau, Mérédis, Venken, Koen, Faict, Sylvia, Maes, Ken, De Veirman, Kim, De Bruyne, Elke, Leleu, Xavier, Boon, Louis, Elewaut, Dirk, Vanderkerken, Karin, Menu, Eline
Publicat a Haematologica (2017)

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

per De Smedt, Eva, Devin, Julie, Muylaert, Catharina, Robert, Nicolas, Requirand, Guilhem, Vlummens, Philip, Vincent, Laure, Cartron, Guillaume, Maes, Ken, Moreaux, Jerome, De Bruyne, Elke
Publicat a Blood Adv (2021)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

per Maes, Ken, De Smedt, Eva, Kassambara, Alboukadel, Hose, Dirk, Seckinger, Anja, Van Valckenborgh, Els, Menu, Eline, Klein, Bernard, Vanderkerken, Karin, Moreaux, Jérôme, De Bruyne, Elke
Publicat a Oncotarget (2014)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

per Maes, Anke, Maes, Ken, Vlummens, Philip, De Raeve, Hendrik, Devin, Julie, Szablewski, Vanessa, De Veirman, Kim, Menu, Eline, Moreaux, Jerome, Vanderkerken, Karin, De Bruyne, Elke
Publicat a Blood Cancer J (2019)